Identification and optimisation of a risk stratified cohort of patients with Type 2 diabetes (T2D) across East Belfast Federation through the delivery of a pharmacist-led virtual and face to face service
This Joint Working project between Boehringer Ingelheim Ltd (BIL) and Federation of Family Practices East Belfast (FFPEB) aims to explore a new model of care for diabetes primary care reviews by expanding the role of General Practice Pharmacists (GPPs). GPPs’ will be upskilled in the management of patients with T2D, and in the utilisation of virtual reviews.
This project will support the delivery of safe, high quality, evidence-based, clinically effective, and cost-effective diabetes care in the community and address the backlog of patient reviews.
The project aims to:
Identify and risk stratify patients for review who have either no relevant phlebotomy records in the previous 12 months or those with phlebotomy but not at their personalised target.
Prevent unscheduled diabetes-related healthcare resource use within the Federation by introducing timely, high value interventions aligned to the Gold Standard 15 Care process.
Help provide specialist, dedicated education and training support to existing practice pharmacists to upskill them in diabetes patient management and review.
Enable patients diagnosed with diabetes in the Federation to access healthcare reviews both virtually and face to face.
Enable diabetes patients to better manage their disease with appropriate support closer to home.
This pilot started in May 2022 and is anticipated to complete by the end of May 2024.
Boehringer Ingelheim Limited is pleased to collaborate with Federation of Family Practices East Belfast, to implement a data-led quality improvement programme supported by the upskill of GPPs, to improve patient outcomes in diabetes.
NP-GB-102900 V3 April 2024